Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ayahuasca/Tobacco/Nicotine Use Disorder (TUD)

Ayahuasca for Tobacco/Nicotine Use Disorder (TUD)

8 papers and 0 clinical trials exploring ayahuasca as a treatment for tobacco/nicotine use disorder (tud).

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

8 papers
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Open Accessindividual

Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil

This survey study (n=411) assessed the factors that predict smoking cessation in people who reported quitting or reducing smoking following ayahuasca consumption. Mystical experience and frequency of ayahuasca intake were protective factors, while positive mood (measured by the MEQ30) during the ayahuasca experience was a risk factor. Qualitative analysis revealed eight themes related to the process of smoking cessation/reduction.

Published
February 18, 2022
Journal
Psychopharmacology
Authors
Maia, L. O., Massarentti, C. M., Tófoli, L.F.
Paywallindividual

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Using nationally representative US survey data (NSDUH 2005–2014), lifetime use of classic psychedelics was associated with lower odds of past‑year hypertension after adjustment (adjusted odds ratio 0.86, 95% CI 0.81–0.91), an effect driven specifically by lifetime tryptamine use (aOR 0.80, 95% CI 0.73–0.89). These cross‑sectional findings suggest a potential protective link but cannot establish causality; randomised controlled trials are needed to probe mechanisms and causal effects on blood pressure.

Published
May 1, 2021
Journal
Hypertension
Authors
Simonsson, O., Hendricks, P. S., Carhart-Harris, R., Kettner, H., Osika, W.
Paywallmeta

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies

This review (2021; s=9) of ayahuasca for substance use disorders (SUDs; e.g. alcoholism) found improvements in both rodents and humans who were suffering from SUDs (also on scores of anxiety and depression). The human studies were observational (vs RCTs) thus lacking the power to (confidently) infer causality.

Published
April 29, 2021
Journal
European Archives of Psychiatry and Clinical Neuroscience
Authors
Rodrigues, L. S., Rossi, G. N., Rocha, J. M., Osório, F. L., Bouso, J. C., Hallak, J. E., Dos Santos, R. G.
Paywallmeta

Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature

This paper (2021) reviews the current literature regarding LSD, psilocybin, ketamine, ibogaine, and ayahuasca as potential treatments for addiction. The authors conclude that the available evidence is promising, but that more robust research is needed.

Published
March 31, 2021
Journal
SN Comprehensive Clinical Medicine
Authors
Nigam, K. B., Pandurangi, A. K.
Open Accessindividual

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

This survey study (n=1947) indicates an association between reduced current tobacco and alcohol use and attendance of religious ayahuasca ceremonies. Lifetime use of these substances, however, was higher in the ceremony-attending group in most age groups.

Published
April 24, 2018
Journal
Frontiers in Psychiatry
Authors
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P., Hoy, R., Berro, L. F., Marinho, E. A. V., Areco, K., Winkelman, M. J.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Tobacco/Nicotine Use Disorder (TUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full Ayahuasca profile Full Tobacco/Nicotine Use Disorder (TUD) profile